A5042011351- Retinal Diseases and Treatments
- Retinal Imaging and Analysis
- Retinal and Optic Conditions
- Glaucoma and retinal disorders
- Retinopathy of Prematurity Studies
- Retinal Development and Disorders
- Diabetes Management and Research
- Retinal and Macular Surgery
- Angiogenesis and VEGF in Cancer
- Optical Imaging and Spectroscopy Techniques
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Intraocular Surgery and Lenses
- Advanced Glycation End Products research
- Blood Pressure and Hypertension Studies
- Retinoids in leukemia and cellular processes
- Optical Coherence Tomography Applications
- Neurological Disorders and Treatments
- Diabetes and associated disorders
- Acute Ischemic Stroke Management
- Blood Coagulation and Thrombosis Mechanisms
- Ophthalmology and Visual Impairment Studies
- Chronic Kidney Disease and Diabetes
- Ocular Diseases and Behçet’s Syndrome
- Diabetes Treatment and Management
- Diabetes, Cardiovascular Risks, and Lipoproteins
Joslin Diabetes Center
2016-2025
Harvard University
2016-2025
Jaeb Center for Health Research
2010-2024
Massachusetts Eye and Ear Infirmary
1999-2023
Takasago (Japan)
2019
Mayo Clinic
2019
Takatsuki General Hospital
2018
Massachusetts Eye Research and Surgery Institute
1995-2016
Harvard University Press
1996-2015
American University of Beirut
2014
Retinal ischemia induces intraocular neovascularization, which often leads to glaucoma, vitreous hemorrhage, and retinal detachment, presumably by stimulating the release of angiogenic molecules. Vascular endothelial growth factor (VEGF) is an endothelial-cell-specific whose production increased hypoxia.
The relative efficacy and safety of intravitreous aflibercept, bevacizumab, ranibizumab in the treatment diabetic macular edema are unknown.
The majority of severe visual loss in the United States results from complications associated with retinal neovascularization patients ischemic ocular diseases such as diabetic retinopathy, vein occlusion, and retinopathy prematurity. Intraocular expression angiogenic protein vascular endothelial growth factor (VEGF) is closely correlated these human disorders ischemia-induced mice. In this study, we evaluated whether vivo inhibition VEGF action could suppress a murine model retinopathy....
Diabetic retinopathy is the most frequent cause of new cases blindness among adults aged 20 –74 years. During first two decades disease, nearly all patients with type 1 diabetes and 60% 2 have retinopathy. In Wisconsin Epidemiologic Study Retinopathy (WESDR), 3.6% younger-onset (type diabetes) 1.6% olderonset were legally blind. group, 86% was attributable to diabetic older-onset in which other eye diseases common, one-third legal due NATURAL HISTORY OF DIABETIC RETINOPATHY progresses from...
Diabetic retinopathy is a leading cause of adult vision loss and blindness. Much the retinal damage that characterizes disease results from vascular leakage nonperfusion. This study shows diabetic nonperfusion are temporally spatially associated with leukocyte stasis (leukostasis) in rat model streptozotocin-induced diabetes. Retinal leukostasis increases within days developing diabetes correlates increased expression intercellular adhesion molecule-1 (ICAM-1). ICAM-1 blockade mAb prevents...
Panretinal photocoagulation (PRP) is the standard treatment for reducing severe visual loss from proliferative diabetic retinopathy. However, PRP can damage retina, resulting in peripheral vision or worsening macular edema (DME).To evaluate noninferiority of intravitreous ranibizumab compared with acuity outcomes patients retinopathy.Randomized clinical trial conducted at 55 US sites among 305 adults retinopathy enrolled between February and December 2012 (mean age, 52 years; 44% female; 52%...
Increased vascular permeability and excessive neovascularization are the hallmarks of endothelial dysfunction, which can lead to diabetic macular edema proliferative retinopathy in eye. Vascular growth factor (VEGF) is an important mediator ocular a known vasopermeability nonocular tissues. In these studies, we demonstrate that intravitreal injection VEGF rapidly activates protein kinase C (PKC) retina at concentrations observed clinically, inducing membrane translocation PKC isoforms alpha,...
To evaluate the extent of pancreatic β-cell function in a large number insulin-dependent diabetic patients with disease duration 50 years or longer (Medalists).Characterization clinical and biochemical parameters 411 Medalists correlation postmortem morphologic findings 9 Medalists.The Medalist cohort, mean ± SD age 56.2 5.8 67.2 7.5 years, respectively, has phenotype similar to type 1 diabetes (type diabetes): onset at 11.0 6.4 BMI 26.0 5.1 kg/m(2), insulin dose 0.46 0.2 u/kg, ∼94% positive...
<h3>Importance</h3> Biomarkers that predict future visual acuity (VA) in eyes with baseline diabetic macular edema (DME) would substantively improve risk assessment, management decisions, and selection of for clinical studies targeting DME. <h3>Objective</h3> To determine whether or early change the novel spectral domain–optical coherence tomography (SD-OCT) parameter disorganization retinal inner layers (DRIL) is predictive VA center-involved <h3>Design, Setting, Participants</h3> At a...
OBJECTIVE To assess complication prevalence and identify protective factors in patients with diabetes duration of ≥50 years. Characterization a complication-free subgroup this cohort would suggest that some individuals are protected from complications allow identification endogenous factors. RESEARCH DESIGN AND METHODS Cross-sectional, observational study 351 U.S. residents who have survived type 1 for years (Medalists). Retinopathy, nephropathy, neuropathy, cardiovascular disease were...
Significance Vascular complications are the main cause of morbidity and mortality in diabetic population. Clinical trials show a persistence benefit from early application intensive therapy for glycemic control patients, phenomenon referred to as metabolic memory. The mechanisms underlying memory not fully understood. In this study, using two groups type 1 patients with without development sets genomic DNAs collected 16–17 y apart same we showed persistency DNA methylation over time at key...
Despite treatment advances, diabetic eye disease remains a leading cause of visual acuity (VA) loss worldwide. No methods to prospectively determine which patients will gain or lose vision exist, limiting individualized risk assessment and management. We investigated whether noninvasive, readily obtainable spectral domain optical coherence tomography parameters were correlated with VA in eyes current resolved center-involved macular edema (DME). Images evaluated for disorganization the...